Penn State to Participate in Researching Potential Treatment for Pediatric Brain Cancer
A new collaboration between Penn State College of Medicine and Targepeutics seeks to advance research into a promising combination therapy that offers hope to families with children diagnosed with DIPG (diffuse intrinsic pontine glioma). This glioma is devastating and currently has limited therapy options. Patients diagnosed with this cancer survive for less than a year on average. A new combo therapy involving an immunotoxin dubbed GB13 and radiotherapy has shown promise in preclinical trials where approaches like chemotherapy or targeted therapy have had dismal results. The collaboration seeks to advance this treatment to clinical studies and eventual approval by the FDA. The planned clinical trial seeks to recruit pediatric participants, a reflection of how…
